Abstract
BALB/c mice were immunized by highly immunogenic recombinant proteins containing amino acid sequence of integrin antagonist AP25. Antibody against AP25 was prepared and purified by affinity chromatography. An indirect enzyme-linked immunosorbent assay for qualitative analysis of AP25 in rat plasma samples was successfully established. The assay was successfully applied to determine the pharmacokinetic parameters of AP25 in SD rats by intravenous administration of AP25 and then the rat plasma protein binding of AP25 were determined in vitro. In order to investigate the specificity of ELISA for detection of prototype AP25 in plasma, the proportion of AP25 prototype drug in the ELISA signal value was validated by HPLC. These results can serve as valuable future clinical trials.
Keywords: Integrin antagonist, AP25, indirect ELISA, pharmacokinetics, plasma protein binding rate, HPLC
Protein & Peptide Letters
Title:Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma
Volume: 20 Issue: 5
Author(s): Yongbing Li, Hanmei Xu, Jialiang Hu, Fengguo Zhang, Zhendong Liu, Chi Zhang, Yongjing Yang, Chunyan Pu, Linqiu Huang and Xin Wen
Affiliation:
Keywords: Integrin antagonist, AP25, indirect ELISA, pharmacokinetics, plasma protein binding rate, HPLC
Abstract: BALB/c mice were immunized by highly immunogenic recombinant proteins containing amino acid sequence of integrin antagonist AP25. Antibody against AP25 was prepared and purified by affinity chromatography. An indirect enzyme-linked immunosorbent assay for qualitative analysis of AP25 in rat plasma samples was successfully established. The assay was successfully applied to determine the pharmacokinetic parameters of AP25 in SD rats by intravenous administration of AP25 and then the rat plasma protein binding of AP25 were determined in vitro. In order to investigate the specificity of ELISA for detection of prototype AP25 in plasma, the proportion of AP25 prototype drug in the ELISA signal value was validated by HPLC. These results can serve as valuable future clinical trials.
Export Options
About this article
Cite this article as:
Li Yongbing, Xu Hanmei, Hu Jialiang, Zhang Fengguo, Liu Zhendong, Zhang Chi, Yang Yongjing, Pu Chunyan, Huang Linqiu and Wen Xin, Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma, Protein & Peptide Letters 2013; 20 (5) . https://dx.doi.org/10.2174/0929866511320050012
DOI https://dx.doi.org/10.2174/0929866511320050012 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Cell Cannibalism: A Primeval Option to Survive.
Current Molecular Medicine The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Progress in Nanoparticulate Systems for Peptide, Proteins and Nucleic Acid Drug Delivery
Current Pharmaceutical Biotechnology Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Polymeric Drug Delivery Approaches for Colon Targeting: A Review
Drug Delivery Letters Adiponectin as a Potential Therapeutic Target for Prostate Cancer
Current Pharmaceutical Design Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Current Cancer Therapy Reviews Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry Nitric Oxide-Releasing Non Steroidal Anti-Inflammatory Drugs: A New Generation of Anti-Tumoral Molecules
Current Cancer Drug Targets New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook
Current Drug Delivery Identification of Biomarkers and Functional Modules from Genomic Data in Stage-wise Breast Cancer
Current Bioinformatics Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Glycosylation Pathways as Drug Targets for Cancer: Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry